You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026
Filter Results
Select search scope: search across all journals or within the current journal
Search this journal
Enter search terms…
/
You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026
Select search scope: search across all journals or within the current journal
Journal Highlights
Therapeutic Advances in Drug Safety is a peer-reviewed open access journal which focuses on pioneering efforts and innovative studies across all areas of drug safety. Please see the Aims and Scope tab for further information.
The journal is a member of the Committee on Publication Ethics (COPE).
Diversity, Equity and Inclusion Statement
Therapeutic Advances in Drug Safety (TADS) promotes inclusive, open science that reflects the disciplinary, human, and geographic diversity of the drug safety community.
Diversity as a core value embodies inclusiveness, mutual respect, and multiple perspectives.
We welcome editors, editorial board members, peer reviewers and authors from all backgrounds, cultures, ethnicities, nationalities, races, religions, sexes, sexual orientations, gender identities, mental or physical (dis)abilities, ages, career stages, socioeconomic status or any other individual status.
We are committed to continually improving our editorial and review processes whilst playing our part in eradicating bias and inequality in all forms.
Submission information
Submit your manuscript today at http://mc.manuscriptcentral.com/tads.
Please see the Submission Guidelines tab for more information on how to submit your article to the journal.
Open access information
The article processing charge (APC) for this journal is currently $3000 USD. The APC for a Plain Language Summary is $5000.
The APC is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Please see further details here.
Contact
Please direct any enquiries to tads@sagepub.co.uk.
This journal changed its publication mode from subscription to open access in 2019.